Healthcare -
Medical - Healthcare Plans - NASDAQ - US
$ 3.57
-1.92 %
$ 1.79 B
Market Cap
-18.79
P/E
1. INTRINSIC VALUE
Balance Sheet
Clover Health Investments, Corp.
| Current Assets | 428 M |
| Cash & Short-Term Investments | 243 M |
| Receivables | 114 M |
| Other Current Assets | 71.5 M |
| Non-Current Assets | 143 M |
| Long-Term Investments | 120 M |
| PP&E | 8.46 M |
| Other Non-Current Assets | 14.4 M |
| Current Liabilities | 261 M |
| Accounts Payable | 37.2 M |
| Short-Term Debt | 1.66 M |
| Other Current Liabilities | 222 M |
| Non-Current Liabilities | 23.2 M |
| Long-Term Debt | 3 M |
| Other Non-Current Liabilities | 20.2 M |
EFFICIENCY
Earnings Waterfall
Clover Health Investments, Corp.
| Revenue | 2.03 B |
| Cost Of Revenue | 1.78 B |
| Gross Profit | 257 M |
| Operating Expenses | 466 M |
| Operating Income | -209 M |
| Other Expenses | 4.82 M |
| Net Income | -213 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clover Health Investments, Corp.
| Net Income | -213 M |
| Depreciation & Amortization | 2.51 M |
| Capital Expenditures | -584 K |
| Stock-Based Compensation | 141 M |
| Change in Working Capital | -55.4 M |
| Others | -50.7 M |
| Free Cash Flow | -116 M |
Wall Street Analysts Price Targets
Clover Health Investments, Corp.
Wall Street analysts predict an average 1-year price target for CLOV of $3.76 , with forecasts ranging from
a
low of
$1.8 to a high of $6 .
CLOV Lowest Price Target
Wall Street Target
1.8 USD
-49.58%
CLOV Average Price Target
Wall Street Target
3.76 USD
5.32%
CLOV Highest Price Target
Wall Street Target
6 USD
68.07%
4. DIVIDEND
ANALYSIS
CLOV does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Clover Health Investments, Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
2 M USD 1
6-9 MONTHS
136 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
6 months ago
Aug 09, 2024
|
Bought
1 M USD
|
Garipalli Vivek
director, 10 percent owner:
|
+ 531700
|
1.88 USD |
|
8 months ago
Jun 17, 2024
|
Bought
1 M USD
|
Garipalli Vivek
director, 10 percent owner:
|
+ 877567
|
1.14 USD |
|
9 months ago
May 16, 2024
|
Bought
15 K USD
|
Loengard Anna U
Director
|
+ 15600
|
0.96 USD |
|
9 months ago
May 16, 2024
|
Bought
1.4 K USD
|
Loengard Anna U
Director
|
+ 1485
|
0.94 USD |
|
9 months ago
May 17, 2024
|
Bought
9.3 K USD
|
Loengard Anna U
Director
|
+ 10000
|
0.93 USD |
|
11 months ago
Mar 14, 2024
|
Bought
100 K USD
|
Loengard Anna U
Director
|
+ 137000
|
0.73 USD |
|
11 months ago
Mar 14, 2024
|
Bought
9.95 K USD
|
Loengard Anna U
Director
|
+ 13625
|
0.73 USD |
|
1 year ago
Sep 06, 2023
|
Bought
13 K USD
|
Loengard Anna U
Director
|
+ 10000
|
1.3 USD |
|
1 year ago
Sep 06, 2023
|
Bought
650 USD
|
Loengard Anna U
Director
|
+ 500
|
1.3 USD |
|
1 year ago
Sep 06, 2023
|
Bought
650 USD
|
Loengard Anna U
Director
|
+ 500
|
1.3 USD |
|
2 years ago
Mar 11, 2022
|
Bought
248 K USD
|
SHAPIRO LEE
director:
|
+ 80000
|
3.1009 USD |
|
3 years ago
Mar 03, 2022
|
Bought
253 K USD
|
Clinton Chelsea
director:
|
+ 100000
|
2.5253 USD |
|
3 years ago
Nov 22, 2021
|
Bought
10 M USD
|
Palihapitiya Chamath
10 percent owner
|
+ 1739130
|
5.75 USD |
7. News
Clover Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025.
globenewswire.com
- 2 weeks ago
Clover Health: Watch Out For Volatility Following Q4 Earnings Results
I remain bullish on Clover Health long-term but prefer to Hold until Q4 2024 earnings for higher conviction before initiating a long position in this stock. I believe the 40% YTD rise and 60% retail ownership increase the risk of profit taking post-earnings, similar to the Q3 panic selloff. On the positive side, the company has recently reported a 27% increase in Medicare Advantage members, surpassing 100,000 lives, with 95% in its 4-Star PPO plan.
seekingalpha.com
- 3 weeks ago
Clover Health Investments Is Building A Competitive Moat
Clover Health Investments, Corp. is a healthcare provider focused on providing Medicare Advantage plans to seniors. The company's proprietary AI technology helps drive higher reimbursement rates and lower cost of care. The company is leaning into demographic and consumer preference tailwinds giving it a unique competitive advantage.
seekingalpha.com
- 1 month ago
Clover Health: Undervalued Turnaround Play With Promising SaaS Potential
Clover Health's revenue rose 8% in Q3 2024, driven by a 7% growth in Medicare Advantage premiums, despite exiting low-margin ACO REACH program. Cost control measures are paying off, with salaries and benefits down 9%, general expenses down 14%, and losses narrowing significantly. Strong cash reserves of $287.9 million and no long-term debt provide a safety net for strategic investments, particularly in the Clover Assistant platform.
seekingalpha.com
- 1 month ago
Focus On Costs, Regulatory Outlook For Health Insurers In Q4'24 Earnings Season
Most publicly traded US health insurers are forecast to report sequential revenue and earnings declines for the fourth quarter of 2024, according to S&P Global Market Intelligence analysis of sell-side analyst forecasts. Coming off a challenging end to 2024, the upcoming earnings season is an opportunity for managed care companies to focus on 2025 expectations and Medicare Advantage growth, according to J.P. Morgan analyst Lisa Gill. UnitedHealth and Oscar Health are expected to log sequential and year-over-year revenue growth.
seekingalpha.com
- 1 month ago
Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period
WILMINGTON, Del., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced a 27% year-over-year growth of its Medicare Advantage (MA) membership during the most recent Annual Election Period (AEP). The Company enters 2025 with over 100,000 members, approximately 95% of whom are enrolled in Clover's flagship 4-Star PPO plan.
globenewswire.com
- 1 month ago
Counterpart Health Deploys Counterpart Assistant with Leading Accountable Care Organization
WILLMINGTON, Del., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced it has successfully deployed its Counterpart Assistant technology within Duke Connected Care (DCC), a recognized leader in accountable care and part of the prestigious Duke University Health System. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover Health”).
globenewswire.com
- 1 month ago
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
zacks.com
- 2 months ago
Recent Earnings Disappointment Could Be An Ideal Buying Opportunity For Clover Health
Clover Health's recent performance shows mixed results, with revenue growth but a significant share price drop, presenting a potential buying opportunity. Operational efficiency is improving, with better adjusted EBITDA and reduced net loss, indicating progress towards profitability. Wall Street remains optimistic, with positive ratings and a potential 46% upside, bolstered by a Medicare Advantage PPO plan upgrade.
seekingalpha.com
- 2 months ago
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Remote-First Company -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. Eastern Time.
globenewswire.com
- 2 months ago
Clover Health: Balancing Innovation And Challenges
Clover Health Investments shows financial progress and challenges in 2024, with a focus on innovative Medicare Advantage plans and technology-driven healthcare solutions. The company achieved a 4.0 rating for its PPO plan, indicating improved quality of care and potential for higher CMS reimbursements. Despite a slight membership decline, Clover's financial efficiency has improved, with net income losses decreasing significantly from 2022 to 2024.
seekingalpha.com
- 2 months ago
Here's Why Clover Health Investments (CLOV) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Clover Health Investments (CLOV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
- 2 months ago
8. Profile
Summary
Clover Health Investments, Corp. CLOV
COUNTRY
US
INDUSTRY
Medical - Healthcare Plans
MARKET CAP
$ 1.79 B
Dividend Yield
0.00%
Description
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Contact
725 Cool Springs Blvd, Franklin, TN, 37067
https://www.cloverhealth.com
IPO
Date
June 12, 2020
Employees
552
Officers
Ms. Jamie L. Reynoso
Chief Executive Officer of Medicare Advantage
Mr. Brady Priest J.D.
Chief Executive Officer of Home Care
Dr. Kumar Dharmarajan
Chief Medical Officer of Clover Assistant
Ms. Wendy Richey
Chief Compliance Officer
Ms. Rachel Fish
Chief People Officer
Ms. Karen Soares
General Counsel, Senior Vice President & Corporate Secretary
Mr. Conrad Wai
Chief Technology Officer
Mr. Peter J. Kuipers
Chief Financial Officer
Mr. Vivek Garipalli
Co-Founder & Executive Chairman
Mr. Andrew Toy
Co-Founder, Chief Executive Officer & Director